PlumX Metrics
Embed PlumX Metrics

Comparison of oral propranolol, oral rifampicin, and intravitreal anti-VEGF in central serous chorioretinopathy

Indian Journal of Ophthalmology, ISSN: 1998-3689, Vol: 71, Issue: 10, Page: 3381-3385
2023
  • 3
    Citations
  • 0
    Usage
  • 4
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Most Recent News

New Findings from Hassan Institute of Medical Sciences in the Area of Central Serous Chorioretinopathy Published (Comparison of oral propranolol, oral rifampicin, and intravitreal anti-VEGF in central serous chorioretinopathy)

2023 OCT 13 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Drug Daily -- New research on central serous chorioretinopathy is the subject

Article Description

Purpose: To compare the efficacy of oral propranolol, oral rifampicin, and intravitreal anti-VEGF therapies on resolution-time and visual outcome in patients with central serous chorioretinopathy (CSCR). Methods: A total of 30 patients with CSCR were randomized into three groups of 10 patients. Group A was given oral propranolol, Group B was given oral rifampicin 4 weeks each, and Group C was given 0.05 ml intravitreal injection of anti-VEGF. Comparisons of mean BCVA, contrast sensitivity, and central macular thickness (CMT) performed between baseline and follow-up at 4 weeks, 6 weeks, and 3 months. Results: Statistically significant improvement in BCVA and contrast sensitivity was noted among all three groups. Complete resolution of SRF as indicated by CMT was seen at the end of 4 weeks in Group C, whereas there was a steady decline in CMT until 3 months in Groups A and B. Conclusion: Intravitreal anti-VEGF therapy shows a significantly faster SRF resolution. However, oral propranolol and oral rifampicin could prove as a useful, cost-effective treatment of CSCR.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know